BeStock  
Stocks › Biotechnology › CORT

Corcept Therapeutics CORT

US equityMarket cap rank #1733Biotechnology
$63.62 −$1.36 (-2.09%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $63.62 0.00%
Open$64.07
Prev close$64.98
Day range$62.81 – $65.13
Volume1.09M
Market cap$6.96B
P/E (TTM)47.8
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$340.47M+64.0% YoY
Operating profit$114.72M+1,022.7% YoY
Net profit$126.78M+544.6% YoY
Diluted EPS$1.01+531.3% YoY
Free cash flow$142.18M+161.0% YoY
Operating cash flow$142.89M

Revenue, last 8 quarters

$181.9MDec '24$157.2MMar '25$194.4MJun '25$207.6MSep '25$202.1MDec '25$164.9MMar '26$256.1MJun '26$340.5MSep '26

Net profit, last 8 quarters

$30.7MDec '24$20.5MMar '25$35.1MJun '25$19.7MSep '25$24.3MDec '25$-31.8MMar '26$43.0MJun '26$126.8MSep '26

Diluted EPS by quarter

0.26Dec '240.17Mar '250.29Jun '250.16Sep '250.20Dec '25-0.30Mar '260.36Jun '261.01Sep '26

Free cash flow by quarter

$59.9MDec '24$4.7MMar '25$44.2MJun '25$54.5MSep '25$38.4MDec '25$-17.0MMar '26$31.0MJun '26$142.2MSep '26

Annual revenue

$353.9MFY20$366.0MFY21$401.9MFY22$482.4MFY23$675.0MFY24$761.4MFY25

Profitability & balance sheet

Gross margin98.5%
Operating margin11.5%
Net margin16.5%
Return on equity21.7%
Return on assets17.2%
Return on invested capital19.9%
Current ratio3.00
Liabilities / assets19.4%
Cash & investments$370.70M
Total debt$6.97M
Net cash (debt)$363.74M
Free cash flow / sales20.2%

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Hypercortisolism Products$208.58M 81.4%
  • Lifyorli$47.56M 18.6%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $340.47M $256.15M $164.90M $761.41M $202.13M
Total Operating Revenue $340.47M $256.15M $164.90M $761.41M $202.13M
Cost of Revenue $4.61M $4.06M $2.88M $12.98M $2.55M
Gross Profit $335.86M $252.09M $162.02M $748.43M $199.58M
Operating Expense $221.14M $210.79M $211.62M $703.63M $195.09M
Selling and Admin Expenses $164.43M $156.90M $145.36M $448.73M $130.24M
Research & Development $56.71M $53.89M $66.27M $254.91M $64.86M
Operating Profit $114.72M $41.30M -$49.60M $44.80M $4.49M
Net Non-Operating Interest Income (Expense) $5.58M $4.63M $4.89M $21.67M $5.42M
Non-Operating Interest Income $5.58M $4.63M $4.89M $21.67M $5.42M
Pretax Profit $120.31M $45.93M -$44.72M $66.46M $9.91M
Tax -$6.47M $2.94M -$12.95M -$33.19M -$14.38M
Net Profit $126.78M $42.99M -$31.76M $99.65M $24.29M
Profit from Continuing Operations $126.78M $42.99M -$31.76M $99.65M $24.29M
Net Income to Parent Company $126.78M $42.99M -$31.76M $99.65M $24.29M
Net Income to Common Stockholders $124.49M $42.14M -$31.20M $98.17M $23.90M
Basic EPS $1.17 $0.40 -$0.30 $0.95 $0.23
Diluted EPS $1.01 $0.36 -$0.30 $0.82 $0.20
Other Preferred Stock Dividends – – -$559,000.00 $1.48M –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.03B $888.70M $814.88M $836.65M $836.65M
Total Current Assets $533.87M $439.68M $426.03M $485.46M $485.46M
Cash and Cash Equivalents & Short-Term Investments $370.70M $308.20M $338.18M $372.15M $372.15M
-Cash and Cash Equivalents $98.72M $111.04M $108.74M $120.50M $120.50M
-Short Term Investments $271.98M $197.16M $229.45M $251.66M $251.66M
Receivables $111.06M $76.92M $39.07M $59.79M $59.79M
-Accounts Receivable $111.06M $76.92M $39.07M $59.79M $59.79M
Prepaid Assets $26.93M $28.59M $25.10M $28.50M $28.50M
Inventory $11.91M $13.19M $12.89M $12.87M $12.87M
Current Deferred Assets $6.07M $4.43M $4.41M $5.06M $5.06M
Other Current Assets $7.21M $8.36M $6.38M $7.10M $7.10M
Total Non-Current Assets $500.15M $449.03M $388.85M $351.19M $351.19M
Net PPE $11.46M $11.99M $10.37M $6.47M $6.47M
-Gross PPE $11.46M $11.99M $10.37M $6.47M $6.47M
Investments and Advances $291.60M $236.45M $177.26M $160.27M $160.27M
-Available for Sale Securities $291.60M $236.45M $177.26M $160.27M $160.27M
Non-Current Deferred Assets $169.07M $178.68M $181.56M $168.20M $168.20M
Other Non-Current Assets $28.02M $21.90M $19.66M $16.25M $16.25M
Total Liabilities $200.29M $182.93M $176.89M $188.85M $188.85M
Total Current Liabilities $177.68M $153.80M $149.19M $166.09M $166.09M
Payables $21.92M $14.91M $33.31M $40.44M $40.44M
-Accounts Payable $21.92M $14.91M $33.31M $40.44M $40.44M
Current Accrued Expenses $39.42M $38.12M $47.68M $44.56M $44.56M
Short-Term Debt and Capital Lease Obligation $2.02M $1.92M $1.63M $1.08M $1.08M
-Current Capital Lease Obligation $2.02M $1.92M $1.63M $1.08M $1.08M
Current Deferred Liabilities $52.50M $45.85M $33.56M $35.68M $35.68M
Other Current Liabilities $9.05M $14.75M $12.14M $6.91M $6.91M
Total Non-Current Liabilities $22.61M $29.12M $27.71M $22.76M $22.76M
Long Term Accounts Payable and Other Payables $15.65M $15.49M $15.33M $15.18M $15.18M
Non-Current Accrued Expenses $0.00 $6.13M $4.37M $2.56M $2.56M
Long Term Debt and Capital Lease Obligation $6.97M $7.50M $8.01M $5.02M $5.02M
-Long Term Capital Lease Obligation $6.97M $7.50M $8.01M $5.02M $5.02M
Total Equity $833.74M $705.78M $637.99M $647.81M $647.81M
Stockholders' Equity $833.74M $705.78M $637.99M $647.81M $647.81M
Capital Stock $144,000.00 $142,000.00 $141,000.00 $140,000.00 $140,000.00
-Common Stock $144,000.00 $142,000.00 $141,000.00 $140,000.00 $140,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.12B $1.05B $1.00B $968.60M $968.60M
Retained Earnings $781.39M $654.61M $611.63M $643.39M $643.39M
Less: Treasury Stock -$1.07B -$998.01M -$976.69M -$966.59M -$966.59M
Gains/Losses Not Affecting Retained Earnings -$1.51M $436,000.00 $918,000.00 $2.26M $2.26M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $142.89M $33.54M -$16.77M $142.00M $38.45M
Net cash flow from continuing operations $142.89M $33.54M -$16.77M $142.00M $38.45M
Net Income from Continuing Operations $126.78M $42.99M -$31.76M $99.65M $24.29M
Depreciation & Depletion & Amortization $1.03M $863,000.00 $598,000.00 $1.89M $482,000.00
Deferred Tax $9.61M $2.88M -$13.11M -$37.54M -$15.18M
Change in Working Capital -$23.25M -$41.90M $5.29M -$1.41M $9.19M
-Change in Receivables -$34.14M -$37.85M $20.71M -$5.81M $9.84M
-Change in Inventory -$5.06M -$4.26M -$3.27M -$7.48M $483,000.00
-Change in Prepaid Assets $1.06M -$3.40M $4.74M -$18.92M -$1.79M
-Change in Payables and Accrued Expense $14.90M $3.61M -$16.88M $30.17M $16,000.00
Net cash flow from investing -$131.99M -$29.24M $4.54M $69.76M -$11.84M
Net Cash Flow from Continuing Investing Activities -$131.99M -$29.24M $4.54M $69.76M -$11.84M
Net PPE Purchase and Sale -$709,000.00 -$2.53M -$201,000.00 -$211,000.00 -$50,000.00
Net Investment Purchase and Sale -$131.28M -$26.71M $4.74M $69.97M -$11.79M
Financing Cash Flow -$23.89M -$2.04M $760,000.00 -$220.37M -$31.22M
Net Cash Flow from Continuing Financing Activities -$23.89M -$2.04M $760,000.00 -$220.37M -$31.22M
Proceeds from Stock Option Exercised $14.06M $9.42M $6.52M -$147.43M $5.32M
Net Other Financing Charges -$37.95M -$11.46M -$5.76M -$72.94M -$36.54M
Ending Cash Balance $99.39M $112.29M $109.99M $120.50M $120.50M
Net Change in Cash -$12.98M $2.26M -$11.47M -$8.61M -$4.61M
Beginning Cash Balance $112.29M $109.99M $121.75M $127.67M $126.14M
Effect of Exchange Rate Changes $78,000.00 $37,000.00 -$287,000.00 $1.44M -$32,000.00
Free Cash Flow $142.18M $31.02M -$16.97M $141.79M $38.40M
-Change in Other Current Assets – – – $1.46M $2.90M
-Change in Other Current Liabilities – – – -$829,000.00 -$251,000.00
Net Common Stock Issuance – – – $0.00 –

Discussion

No comments yet — be the first to weigh in on CORT.

Sign in to join the discussion.

Scroll to Top